Related Experiment Video
Updated: Jul 11, 2026
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Advances in long-term stroke prevention with antiplatelet therapy
1Division of Neurology, Yale University School of Medicine, and Veterans Affairs Medical Center, New Haven, CT 06520-8018, USA.
Insights
Antiplatelet therapies like aspirin, clopidogrel, and dipyridamole are vital for preventing secondary ischemic strokes. Newer treatments offer effective options, but higher aspirin doses increase adverse events without improving efficacy.
Area of Science:
- Neurology
- Cardiology
- Pharmacology
Background:
- Stroke is a primary cause of death and disability globally.
- Antiplatelet therapy is a proven strategy for secondary ischemic stroke prevention.
Purpose of the Study:
- To review the efficacy of various antiplatelet agents in secondary ischemic stroke prevention.
- To highlight recent advancements in antiplatelet therapy for stroke patients.
Main Methods:
- Review of randomized controlled trials evaluating antiplatelet agents.
- Comparative analysis of aspirin, clopidogrel, ticlopidine, and dipyridamole efficacy and safety.
Main Results:
- Aspirin is effective, but higher doses offer no additional benefit and increase adverse events.
- Clopidogrel and ticlopidine demonstrate superior efficacy over aspirin in preventing recurrent ischemic events.
- Combination therapy (aspirin with sustained-release dipyridamole) shows enhanced effectiveness, particularly in reducing nonfatal strokes.
Conclusions:
- Current evidence supports the use of specific antiplatelet agents and combinations for secondary stroke prevention.
- Newer antiplatelet treatment options provide effective strategies to reduce stroke recurrence and associated mortality.
Abstract:
Stroke is a leading cause of mortality and major disability. There is considerable evidence from randomized trials that antiplatelet therapy is effective in the secondary prevention of ischemic strokes. Aspirin, the most widely evaluated agent, has consistently been found to be effective. However, higher doses are no more effective than lower doses and are associated with a higher incidence of adverse events. Clopidogrel has been shown to be more effective than aspirin in preventing recurrent ischemic events in patients with atherosclerosis manifested by ischemic stroke, myocardial infarction, or peripheral arterial disease. Ticlopidine has also been shown to be more effective than aspirin in the reduction of recurrent strokes and in the composite end point of stroke and death. Dipyridamole, in the sustained release formulation, in combination with aspirin, has been shown to be more effective than aspirin alone, particularly in the reduction of nonfatal strokes. Data from recent clinical trials has shown that there are new and effective treatment options available with antiplatelet therapy for the secondary prevention of ischemic stroke.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:27Peripheral Artery Disease III: Interprofessional Care
01:26Atherosclerosis III: Management
01:29Venous Thrombosis III: Interprofessional Care
01:27Coronary Artery Disease V: Interprofessional Care
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...